KREBS BIOCHEMICALS & INDUSTRIES
|
|
| BOM : 524518     NSE : KREBSBIO     | |
| LT :  
    Long Term Analysis
Fundamentals : Bad
Valuation : Bad [Stock is Expensive] Debt : High |
Updated: |
| ST :  
    Short Term Analysis
Quarterly Earnings Trend : Downward
Price Momentum : Downward Pledged Shares : None or < 25% |
Nov 11,2025 |
|
Price(EOD): ₹ 69.94
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
| MCap: ₹ 151.07 Cr | |
| Industry Peers & Returns | 1W | 1M | 1Y |
| KREBS BIOCHEMICALS & INDUSTRIES | 0.6% | -5% | -13.1% |
| SUN PHARMACEUTICAL INDUSTRIES | 1.4% | 3.5% | -5.9% |
| DIVIS LABORATORIES | -3.9% | 6.6% | 15.2% |
| CIPLA | 0.8% | 0.2% | -5.5% |
| TORRENT PHARMACEUTICALS | 7% | 7.8% | 19.8% |
| DR REDDYS LABORATORIES | 0.9% | -2.8% | -5.8% |
| MANKIND PHARMA | -6.3% | -10.5% | -17.6% |
| ZYDUS LIFESCIENCES | -3.6% | -5.8% | -4.3% |
| LUPIN | -1.1% | 0.9% | -8.8% |
FUNDAMENTAL ANALYSIS OF KREBS BIOCHEMICALS & INDUSTRIES
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF KREBS BIOCHEMICALS & INDUSTRIES
 | Ratio | Standalone | |
|---|---|---|
|
P/E P/B P/S |
-5.49
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs -27.47 Cr
[Latest Qtr - Sep2025 - Standalone Results ] -1.03
P/B Calculated based on Book Value of Rs -146.24 Cr
[Latest Year - Mar2025 - Standalone Results ] 5.54
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 0.00 Cr
[Latest Qtr - Sep2025 - Standalone Results ] |
|
| Financial Ratios → | ||
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
NA 128% 30% |
SHARE PRICE MOMENTUM OF KREBS BIOCHEMICALS & INDUSTRIES
KREBS BIOCHEMICALS & INDUSTRIES vs SENSEX
DEBT OF KREBS BIOCHEMICALS & INDUSTRIES
| Year | Debt/Equity ratio | |
|---|---|---|
| Standalone | Consolidated | |
|
2025 2024 2023 Avg_3yrs |
-1.45 -1.62 -1.84 -1.64 |
- - - - |
|
[Last Annual Data : Mar2025]
|
||
| Financial Ratios → | ||
PLEDGED PROMOTER SHARES OF KREBS BIOCHEMICALS & INDUSTRIES
| Pledged Promoter Shares |
0 % | |
|---|---|---|
| As on : Sep2025 | ||
If less than 25% | Good |
|
| If between 25% and 50% | Neutral | |
| If greater than 50% | Bad | |
| Shareholding Pattern → | ||
QTRLY RESULTS OF KREBS BIOCHEMICALS & INDUSTRIES
| Standalone | Q-o-Q | Y-o-Y |
|---|---|---|
|
Revenue Op Profit Profit Before Tax Profit After Tax |
-23.97% -33.83% -15.38% -15.38% |
-67.58% -3.06% -6.63% -6.63% |
| QtrlyTrend |
-8 | |
| Latest Qtr: Sep2025 | ||
| Quarterly Result Analysis → | ||
KREBS BIOCHEMICALS & INDUSTRIES related INDICES
You may also like the below Video Courses
FAQ about KREBS BIOCHEMICALS & INDUSTRIES
Is KREBS BIOCHEMICALS & INDUSTRIES good for long term investment?
As on Nov 11,2025, the Fundamentals of KREBS BIOCHEMICALS & INDUSTRIES look Poor and hence it may not be good for long term investment ! See Financial Performance of KREBS BIOCHEMICALS & INDUSTRIES . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is KREBS BIOCHEMICALS & INDUSTRIES UnderValued or OverValued?
As on Nov 11,2025, KREBS BIOCHEMICALS & INDUSTRIES is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of KREBS BIOCHEMICALS & INDUSTRIES ?
As on Nov 11,2025, the Intrinsic Value of KREBS BIOCHEMICALS & INDUSTRIES is Rs. 42.33 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. -48.10
Fair Value [Median EV / Sales Model] : Rs. 30.74
Fair Value [Median Price / Sales Model] : Rs. 53.91
Estimated Median Fair Value of KREBS BIOCHEMICALS & INDUSTRIES : Rs. 42.33
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.